BioSpace News Archive

ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation.

Viruses in the herpesvirus family are leading causes of birth defects, blindness, and failed organ transplants worldwide.

Cytonus Therapeutics, Inc. , a first-in-class combination drug-delivery and therapeutic platform company with a stated mission to make every biologic therapy better by making them safer, today announced that new pre-clinical data will be presented on May 15, 2022, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), held in Washington, D.C.

The American Diabetes Association®, the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic, is proud to announce Charles D. “Chuck” Henderson as the new Chief Executive Officer.

AltruBio Inc. today announced that enrollment has been completed for the Phase 1 clinical study of neihulizumab (ALTB-168) in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD).

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update at the end of March 2022.

Prometheus Biosciences, Inc. reported financial results for the quarter ended March 31, 2022 and highlighted recent corporate progress.

Ventyx Biosciences, Inc. announced financial results for the first quarter ended March 31, 2022 and highlighted recent pipeline and business progress.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the first quarter that ended March 31, 2022.

Aptose Biosciences Inc. announced that the company management team, along with guest key opinion leaders, will provide an update for the investment community on Thursday, June 2nd at 4:30 PM.